Applications are open globally; USA and international companies are encouraged to apply.
ABOUT THE SUMMIT AND AWARD
The Lyfebulb-Veloxis Innovation Challenge will take place in October 2022 at Veloxis’ headquarters and is currently accepting applications through August 21, 2022. Selected applicants (i.e., finalists) will receive an invitation to pitch their ideas and business solutions live to an expert panel of judges comprised of healthcare industry, medical, and patient leaders over the course of a two-day summit.
Prizes will be awarded to two finalists to further grow their companies. The Innovation Award will be presented to a for-profit company and includes $25,000 monetary grant. The Impact Award will be presented to a not-for-profit company and includes $15,000 monetary grant. Competing finalists may be considered by Veloxis for possible partnerships or investment opportunities.
In addition to the pitch competition, finalists will have the opportunity to engage with representatives from the patient community, industry, Lyfebulb, and Veloxis through workshops and learning hubs.
KEY PILLARS OF INNOVATION
Through Lyfebulb and Veloxis Pharmaceutical’s shared commitment to patients and their loved ones, the Lyfebulb-Veloxis Innovation Challenge is seeking a wide range of solutions to improve lived-experience and outcomes for all those affected by transplant:
- New treatments, methods and/or procedures
- Diagnostics and patient monitoring
- System-wide improvements to care
- Advancements in health equity
- Quality of life
- Patient services
Solutions may any stage of the patient journey from pre-transplant to post-transplant longer-term management. Examples include, but are not limited to: organ supply, rejection, transplant procedures, comorbidities / side effects, patient education, and dialysis.
CRITERIA FOR APPLYING TO THE CHALLENGE
- Drugs / therapeutics
- Devices / technology
- Individuals with registered companies
STAGES OF DEVELOPMENT
- Idea stage
- Early development
- Mature development
The judging panel will assess the following:
Strategic basis for addressing unmet needs facing patients, care partners, and/or professionals
Demonstrated ability of the innovation to address
Potential of the innovation to improve outcomes or lived-experience of people affected by transplant
Degree of market impact and patient impact
Measurability of impact
Uniqueness to the market
Feasibility of development and implementation
THE CHALLENGE IN NUMBERS
Applications close on Wednesday, August 21, 2022, at 11:59 PM EDT
The Challenge will take place
October 13 – 14, 2022
One entrepreneur will be awarded the Innovation Award, including $25,000
One entrepreneur will be awarded the Impact Award, including $15,000
The 2022 Innovation Challenge is one component of a larger partnership between Lyfebulb and Veloxis Pharmaceuticals, which is built upon a shared commitment to advancing patient-driven innovation in transplantation to attain improved outcomes for patients as well as care partners. The Lyfebulb Innovation Challenge, sponsored by Veloxis Pharmaceuticals, stems from the concept of the Lyfebulb Entrepreneur Circle established in 2015, which features individuals who have created a product and/or a company in response to their personal experiences with a chronic illness (through their own diagnosis or that of a loved one).
Additionally, Veloxis Pharmaceuticals is sponsoring a transplant education series in partnership with Lyfebulb and Columbia University. Information and recordings of webinars from this series can be found on TransplantLyfe, Lyfebulb’s digital platform for transplant patients and care partners, at www.transplantlyfe.com/webinars.